Acute generalized exanthematous pustulosis (AGEP)

• (2014): Lin YF+, Clin Infect Dis 58(10), 1377

Anaphylactoid reactions / anaphylaxis (includes anaphylactic shock)

• (2024): Butranova O+, Pharmaceuticals (Basel) 17(1), 9045% (pharmacovigilance)
• (2020): Yu RJ+, J Allergy Clin Immunol Pract Sep, Online ahead of print [REVIEW]

Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))

• (2025): Kong J+, Clin Exp Allergy Apr, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
• (2023): Wung CH+, Front Pharmacol Apr (e-Collection) [REVIEW] (pharmacogenomics)
• (2022): Martins JC+, An Bras Dermatol Apr, Online ahead of print
• (2021): Villanueva-Paz M+, J Clin Med 10(22), 5317 [REVIEW]

DRESS syndrome (Drug-induced hypersensitivity syndrome / DIHS)

• (2023): Alotaibi M, Cureus 15(3), e35701 [REVIEW]
• (2014): Lin YF+, Clin Infect Dis 58(10), 1377

Henoch-Schönlein purpura / IgA vasculitis / immunoglobulin A vasculitis

• (2025): Zheng H+, Arch Dermatol Res 317(1), 383 [REVIEW] (pharmacovigilance / pharmacoepidemiology)

Hypersensitivity

• (2025): Biswas M+, Front Pharmacol Oct (e-Collection) [REVIEW] (pharmacogenomics)

Pruritus (itching)

• (2023): Nakao Y+, Pharmaceuticals (Basel) 16(10), 1500 (FDA Adverse Event Reporting System data)

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN)

• (2014): Lin YF+, Clin Infect Dis 58(10), 1377
• (2014): Su P+, Int J Dermatol 53(11), 1339

Toxic epidermal necrolysis (Lyell's syndrome)

• (2014): Lin YF+, Clin Infect Dis 58(10), 1377

Oral changes

• (2020): Aziz Y+, Oral Dis Oct, Online ahead of print [REVIEW]

Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))

• (2025): Kaur N+, Mol Biol Rep 52(1), 319 [REVIEW]

Ageusia (taste loss) / taste disorder

• (2021): Kan Y+, Sci Rep 11(1), 9625 [REVIEW]

Anosmia (smell loss) / smell disorder

• (2021): Kan Y+, Sci Rep 11(1), 9625 [REVIEW]

Mania

• (2017): Lambrichts S+, J Affect Disord 219, 149-156 (47 cases) [REVIEW]
• (2002): Abouesh A+, J Clin Psychopharmacol 22(1), 71-81 [REVIEW]

Neurological adverse effect / neurological deficit

• (2023): Lacroix C+, Therapie Oct, Online ahead of print (association)

Neuropsychiatric / neuropsychological adverse effect

• (2025): Cattaneo D+, Ther Drug Monit May, Online ahead of print [REVIEW]

Psychosis

• (2020): Essali N+, Brain Behav Immun Health Sep (e-Collection) [REVIEW]

Esophagitis

• (2022): Abdi S+, Gastroenterol Hepatol Bed Bench 15(3), 219-224 [REVIEW]

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)

• (2025): Björnsson RA+, Drug Saf Mar, Online ahead of print [REVIEW] (Revised Electronic Causality Assessment Method) (pharmacovigilance / pharmacoepidemiology)
• (2021): Kong X+, Br J Clin Pharmacol May, Online ahead of print [REVIEW]
• (2021): Villanueva-Paz M+, J Clin Med 10(22), 5317 [REVIEW]

Hematological inflammatory markers raised

• (2019): Eom KS, J Korean Neurosurg Soc May, Epub ahead of print (2 cases)

Neutropenia (neutrophils decreased)

• (2022): Battini V+, Front Pharmacol Jun (e-Collection)

Thrombocytopenia / platelets decreased

• (2021): Asai Y+, Int J Toxicol Oct, Online ahead of print

Ototoxicity

• (2020): Rizk HG+, Pharmacotherapy Oct, Online ahead of print [REVIEW]

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury

• (2022): Rey A+, Fundam Clin Pharmacol Jan, Online ahead of print

Pulmonary embolism

• (2025): Adusumilli PK+, Perspect Clin Res 16(1), 44-49 (pharmacovigilance / pharmacoepidemiology)

Adverse effects / adverse reactions

• (2022): Barbosa LHLA+, Front Pharmacol Sep (e-Collection) [REVIEW]
• (2022): Browning S+, Clin Microbiol Infect Jan, Online ahead of print3% ('major') (intravenous administration)
• (2022): Leporini C+, Drug Saf Sep, Online ahead of print [REVIEW]

Adverse pregnancy outcomes

• (2025): Nguyen J+, Pharmacotherapy Mar, Online ahead of print [REVIEW]